This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
SITC 2021
Presentations

SEA-TGT | Advanced Malignancies | Poster #474
Phase 1 study of SEA-TGT, a human, nonfucosylated monoclonal antibody directed to TIGIT with enhanced immune effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress)

SGN-B7H4V | Preclinical | Poster #854
SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models

SGN-PDL1V | Solid Tumors | Poster #783
SGN-PDL1V, a novel, investigational PD-L1 directed antibody drug conjugate for the treatment of solid tumors